Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma

被引：1
|
作者：
Gondran, Camille [1 ]
Ysebaert, Loic [1 ]
机构：
[1] Inst Univ Canc Toulouse, Serv dh matol, F-31100 Toulouse, France
来源：
BULLETIN DU CANCER | 2022年 / 109卷 / 11期
关键词：
Follicular lymphoma; Mosunetuzumab; Bi-specific antibody CD20-CD3; Cytokine release syndrome;
D O I：
10.1016/j.bulcan.2022.07.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1105 / 1106
页数：2
相关论文
共 50 条
  • [1] Treatment of relapsed or refractory follicular Lymphoma Tisagenlecleucel: EU Approval as Third-line Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8)
  • [2] Evolving Third-Line Treatment Options for Follicular Lymphoma
    Burke, John M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (06) : 394 - 396
  • [3] FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma
    Nierengarten, Mary Beth
    CANCER, 2023, 129 (10) : 1465 - 1466
  • [4] Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
    Nastoupil, Loretta J.
    Bonner, Ashley
    Wang, Pearl
    Almuallem, Lamees
    Desai, Jigar
    Farazi, Thalia
    Kumar, Jinender
    Dahiya, Saurabh
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2025, 14 (01)
  • [5] The end of the line? A case of drug resistance to third-line antiretroviral therapy
    Rossouw, Theresa M.
    Hitchcock, Sonia
    Botes, Maritte
    SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, 2016, 17 (01)
  • [6] Mosunetuzumab for the treatment of follicular lymphoma
    Labanca, Caterina
    Martino, Enrica Antonia
    Vigna, Ernesto
    Bruzzese, Antonella
    Mendicino, Francesco
    De Luca, Paola
    Lucia, Eugenio
    Olivito, Virginia
    Fragliasso, Valentina
    Neri, Antonino
    Morabito, Fortunato
    Gentile, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (10) : 1039 - 1048
  • [7] Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective
    Matasar, Matthew
    Rosettie, Katherine L.
    Lin, Shih-Wen
    Wu, Mei
    Ma, Esprit
    BLOOD, 2024, 144 : 5029 - 5030
  • [8] Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
    Bosch, Francesc
    Kuruvilla, John
    Vassilakopoulos, Theodoros P.
    Di Maio, Danilo
    Wei, Michael C.
    Zumofen, Marie-Helene Blanchet
    Nastoupil, Loretta J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (02): : 105 - 121
  • [9] Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)
    Olszewski, Adam J.
    Huntington, Scott F.
    Bannerji, Rajat
    Ollila, Thomas A.
    McMahon, Jessica
    Dubielecka, Patrycja M.
    BLOOD, 2022, 140 : 6492 - 6493
  • [10] Enzalutamide effective as third-line therapy
    Nature Reviews Urology, 2014, 11 (2) : 67 - 67
12345